Inclusion Criteria:

        - Diagnosis of multiple myeloma as documented per International Myeloma Working Group
        (IMWG) criteria Monoclonal plasma cells in the bone marrow greater than or equal to (>=)10
        percentage (%) or presence of a biopsy proven plasmacytoma and documented multiple myeloma
        satisfying at least one of the calcium, renal, anemia, bone (CRAB) criteria or biomarkers
        of malignancy criteria. CRAB criteria: Hypercalcemia: serum calcium greater than (>) 0.25
        millimoles per liter (mmol/L) (>1 milligram per deciliter [mg/dL]) higher than upper limit
        of normal (ULN) or >2.75 mmol/L (>11 mg/dL); Renal insufficiency: creatinine clearance less
        than (<) 40 milliliter per minute (mL/min) or serum creatinine >177 micro millimoles per
        liter (umol/L) (>2 mg/dL); Anemia: hemoglobin >2 g/dL below the lower limit of normal or
        hemoglobin <10 g/dL; Bone lesions: one or more osteolytic lesions on skeletal radiography,
        computed tomography (CT), or positron emission tomography (PET)-CT.

        Biomarkers of Malignancy: Clonal bone marrow plasma cell percentage >=60%; Involved:
        uninvolved serum free light chain (FLC) ratio >=100; >1 focal lesion on magnetic resonance
        imaging (MRI) studies

          -  Must have measurable disease, as assessed by central laboratory

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2

          -  A woman of childbearing potential must have 2 negative serum or urine pregnancy tests
             at Screening, first within 10 to 14 days prior to dosing and the second within 24
             hours prior to dosing

          -  A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted
             reproduction during the study and for a period of 3 months after receiving the last
             dose of any component of the treatment regimen

        Exclusion Criteria:

          -  Frailty index of >=2 according to Myeloma Geriatric Assessment score

          -  Prior therapy for multiple myeloma other than a short course of corticosteroids (not
             to exceed 40 mg of dexamethasone, or equivalent per day, total of 160 mg dexamethasone
             or equivalent)

          -  Prior or concurrent invasive malignancy (other than multiple myeloma) within 5 years
             of date of randomization (exceptions are adequately treated basal cell or squamous
             cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or other
             non-invasive lesion that in the opinion of the investigator, with concurrence with the
             sponsor's medical monitor, is considered cured with minimal risk of recurrence within
             3 years)

          -  Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the
             National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
             Version 5

          -  Focal radiation therapy within 14 days of randomization with the exception of
             palliative radiotherapy for symptomatic pain management. Radiotherapy within 14 days
             prior to randomization on measurable extramedullary plasmacytoma is not permitted even
             in the setting of palliation for symptomatic management